Invega Sustenna 50 mg (Paliperidone (Paliperidone Palmitate) SUSPENSION (EXTENDED-RELEASE)) 50 MG

Invega Sustenna 50 mg is an extended-release suspension of palperidone palmitate for intramuscular use. It is commonly used in the management of schizophrenia. This medication is designed to provide long-lasting effects with periodic injections.

Strength

50 MG

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Invega Sustenna 50 mg is primarily used for the treatment of schizophrenia in adults. This medication is part of a long-acting injectable therapy, which may help maintain consistent levels of the active ingredient in the body. It is often prescribed for individuals who have difficulty adhering to daily oral medication regimens. The extended-release formulation is intended to simplify treatment and improve compliance.

Side Effects

Common effects of Invega Sustenna 50 mg may include injection site reactions, such as pain, swelling, or redness. Some individuals may experience weight gain, restlessness, or drowsiness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Precautions & Warnings

Invega Sustenna 50 mg should be administered by a healthcare professional experienced in intramuscular injections. It is essential to follow the prescribed dosage and schedule. Patients should be monitored for any signs of allergic reactions or other adverse effects. This medication may cause dizziness or drowsiness, so caution is advised when operating machinery or driving.

Avoid Interactions

Invega Sustenna 50 mg may interact with other medications, including those that affect the central nervous system, such as sedatives or antidepressants. Alcohol consumption should be avoided as it can enhance the sedative effects. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.

Frequently Asked Questions

Invega Sustenna 50 mg is used for the treatment of schizophrenia in adults. It is an extended-release suspension designed for intramuscular injection.

The administration schedule for Invega Sustenna 50 mg is determined by a healthcare provider. It is typically given as an injection every 4 weeks.

Common side effects may include injection site reactions, weight gain, restlessness, and drowsiness. Always consult a healthcare provider for personalized advice.

Invega Sustenna 50 mg may interact with other medications, especially those that affect the central nervous system. Always inform your healthcare provider about all medications you are taking.

Invega Sustenna 50 mg should be used under the supervision of a healthcare provider. It is not suitable for everyone, and individual health conditions should be considered.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.